New Type of Biomarker May Improve Prostate Cancer Care

New Type of Biomarker May Improve Prostate Cancer Care
shutterstock_250914454A new study led by Dr. Andrew Hsieh enabled the identification of two bio-markers that might ameliorate oncologists’ ability to predict which prostate cancers will recur after surgery; this prediction could be done long before the advancement of visible cancer in the patient's body. The findings will be published in Oncotarget. For some men, prostate cancer is a curable illness. However, for those patients where the malignancy metastasises, death is often times inevitable. Pinpointing patients who are at high risk of relapsing is key to enabling early treatment options, as it highly improves effectiveness. Dr. Hsieh managed to identify two predictive biomarkers, and explained in a press release: “once clinically verified, biomarkers like these have the potential to help clinicians identify patients who are more likely to relapse and therefore may benefit from additional therapy after surgery.” Dr. Hsieh’s group showed that the levels of two proteins, YB-1 and MTA1, are inversly connected to prostate cancer recurrence: patients with high amounts of these proteins w
Subscribe or to access all post and page content.

Tagged , , , , .

Isaura Santos graduated with a BS in Cell and Molecular Biology from Universidade Nova de Lisboa and a MA in Communication, Culture and Information Technologies from University Institute of Lisbon (ISCTE-IUL). Her professional interests include science communication, public awareness of science and communication of science through entertainment.

Leave a Comment

Your email address will not be published. Required fields are marked *